Pathway to Cures

Our board member, Amy Dunn, is also Chair of the Medical & Scientific Advisory Council for National Bleeding Disorders Foundation. In this podcast she speaks with Patrick James Lynch regarding the evolution of comprehensive Hemophilia care. #hemophilia #bleedingdisorders #NBDF

Pathway to Cures portfolio company, Afimmune Ltd, will be attending American Society of Hematology meeting this weekend and will share updates on their Phase 2 clinical trial for Epeleuton for Sickle Cell Disease. If you are attending the conference, be sure to connect with them. #rareblooddisorders #sicklecelldisease #ASH24

Pathway to Cures portfolio company Spark Biomedical Inc will be sharing results of their Healthy Human Hemostasis Study exploring the hemostatic effects of vagus nerve stimulation via transcutaneous auricular neurostimulation at the annual American Society of Hematology meeting in San Diego next month. If you are attending the ASH conference, be sure to stop by their booth to learn more about their research of this novel therapy. Pathway to Cures looks forward to continuing to support and catalyze such efforts to advance innovative treatments for inheritable blood and bleeding disorders. #hemostasis #bleedingdisorders #ASH24

Thrilled to hear Rick Morgan, Ph.D., Chief Scientific Officer of Be Biopharma, speak about editing Factor IX into B lymphocytes at the World Federation of Hemophilia / Fédération mondiale de l'hémophilie New Technology and Gene Therapy conference in Montreal, QC today. Pathway to Cures invested in Be Biopharma last month as part of their $82M raise as they transition into clinical trials for the Hemophilia B community. For more details, please see the announcement in the link below: https://lnkd.in/ez6DRUxH

Pathway to Cures is proud to announce the recent investment we made in Be Biopharma in their latest venture round and we are pleased to be included with other partners including: Laura Tadvalkar, RA Capital Management, ARCH Venture Partners, Atlas Venture, Alta Partners, Takeda Ventures, Inc., Longwood Fund, Bristol Myers Squibb, Angus Smith, Christine Brennan, Geeta Vemuri, Brian Andrew, Katherine High, MD, Michael Recht, Steve Pipe, Haiyan Jiang, Glenn Pierce, Leonard Valentino, Philip Gattone, Peter Harvey, @Scott Martin Sharon A. Richardson PhD, Amy Dunn, Teri F. Willey, Tim Brent, and Renee Peck https://lnkd.in/ez6DRUxH

There is still time to register for today's webinar about Hemophilia at 2pm EST. Speakers include our Entrepreneur in Residence, Leonard Valentino, and Scientific Advisory Group co-chair, Glenn Pierce. Please see the link below to sign up. #hemophilia #bleedingdisorders #rarediseases

We are thrilled to see Spark Biomedical Inc participate in the recent Foundation for Women & Girls With Blood Disorders conference. So far, they are seeing great results with the research and development of their wearable neurostimulation device and reducing blood loss in women with heavy menstrual bleeding and VWD. To learn more about the research project and see if you qualify, visit: https://lnkd.in/g8R6MxiQ

Our 2nd annual update meeting took place today at Portal Innovations, LLC in Atlanta. Two of the biotechs we have invested in were with us to share important updates: Dr. Moayed Hamza, CMO of Afimmune Ltd shared an update on their research involving Epeleuton for Sickle Cell Disease and Daniel Powell, CEO of Spark Biomedical Inc shared an update into their Neurostimulation device, Sparrow, for the treatment of heavy menstrual bleeding & Von Willebrand Disease. We are grateful for the sponsorship of Merz Branding and our generous host, Suna L. and Portal Innovations, LLC for the amazing venue and continued partnership. We strive to see a world without inheritable blood and bleeding disorders through our investment into innovative therapies, new technologies, and cures for the community we serve through the National Bleeding Disorders Foundation and Pathway to Cures. #bleedingdisorders #innovation